Wealthspring Capital’s Eucrates Biomedical Acquisition Corp. Unit EUCRU Stock Holding History

Wealthspring Capital’s Portfolio EUCRU Stock Details EUCRU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-130,290	Closed	-$1.31M	–	366
2022 Q3	$1.31M	Buy	130,290 +218	+0.2%	+$2.17K	0.26%	129
2022 Q2	$1.29M	Sell	130,072 -8,301	-6%	-$82.4K	0.24%	135
2022 Q1	$1.36M	Buy	138,373 +13,309	+11%	+$132K	0.27%	127
2021 Q4	$1.25M	Sell	125,064 -636	-0.5%	-$6.39K	0.27%	138
2021 Q3	$1.25M	Buy	125,700 +8,646	+7%	+$86.4K	0.3%	123
2021 Q2	$1.19M	Hold	117,054	–	–	0.3%	117
2021 Q1	$1.18M	Sell	117,054 -12,826	-10%	-$137K	0.32%	92
2020 Q4	$1.39M	Buy	+129,880	New	+$1.32M	0.69%	57

Other funds holding EUCRU

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Wealthspring Capital's EUCRU Position: Q4 2022 in Review

Wealthspring Capital sold out of Eucrates Biomedical Acquisition Corp. Unit (EUCRU) in Q4 2022, closing a stake of 130,290 shares — an estimated $1.31M sold.

Wealthspring Capital first reported a position in EUCRU in Q4 2020 and held it in 8 quarters. The position peaked at $1.39M in Q4 2020. 6 funds tracked by Wall St. Rank hold EUCRU as of Q4 2022.

Wealthspring Capital reported no remaining Eucrates Biomedical Acquisition Corp. Unit position as of Q4 2022 after selling out during the quarter.
Wealthspring Capital sold 130,290 Eucrates Biomedical Acquisition Corp. Unit shares in Q4 2022, an estimated $1.31M.
Wealthspring Capital first reported a position in Eucrates Biomedical Acquisition Corp. Unit in Q4 2020 and held it in 8 quarters.
Wealthspring Capital's Eucrates Biomedical Acquisition Corp. Unit position peaked at $1.39M in Q4 2020.
6 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Unit as of Q4 2022.

Based on Wealthspring Capital's 13F filing for Q4 2022, filed 8 Feb 2023.